AIM ImmunoTech Inc.
AIM
Price:
$0.3065
Market Cap:
$17.51M
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of nat...[Read more]
Industry
Biotechnology
IPO Date
1996-07-12
Stock Exchange
AMEX
Ticker
AIM
The PE Ratio as of September 2024 (TTM) for AIM ImmunoTech Inc. (AIM) is -0.54
According to AIM ImmunoTech Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.54. This represents a change of -55.62% compared to the average of -1.22 of the last 4 quarters.
AIM ImmunoTech Inc. (AIM) Historical PE Ratio (quarterly & annually)
How has AIM PE Ratio performed in the past?
The mean historical PE Ratio of AIM ImmunoTech Inc. over the last ten years is -1.51. The current -0.54 PE Ratio has changed 3.47% with respect to the historical average. Over the past ten years (40 quarters), AIM's PE Ratio was at its highest in in the September 2019 quarter at -0.17. The PE Ratio was at its lowest in in the March 2021 quarter at -7.25.
Average
-1.51
Median
-1.23
Minimum
-3.51
Maximum
-0.18
AIM ImmunoTech Inc. (AIM) PE Ratio by Quarter and Year
Discovering the peaks and valleys of AIM ImmunoTech Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.82%
Maximum Annual PE Ratio = -0.18
Minimum Annual Increase = -77.42%
Minimum Annual PE Ratio = -3.51
| Year | PE Ratio | Change |
|---|---|---|
| 2023 | -0.74 | 3.83% |
| 2022 | -0.71 | -64.89% |
| 2021 | -2.02 | -42.25% |
| 2020 | -3.51 | 1.82% |
| 2019 | -0.18 | -77.42% |
| 2018 | -0.81 | -33.30% |
| 2017 | -1.22 | -39.44% |
| 2016 | -2.01 | 61.77% |
| 2015 | -1.24 | -54.02% |
| 2014 | -2.70 | -3.12% |
AIM ImmunoTech Inc. (AIM) Average PE Ratio
How has AIM PE Ratio performed in the past?
The current PE Ratio of AIM ImmunoTech Inc. (AIM) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.16
5-year avg
-1.43
10-year avg
-1.51
AIM ImmunoTech Inc. (AIM) PE Ratio vs. Peers
How is AIM’s PE Ratio compared to its peers?
AIM ImmunoTech Inc.’s PE Ratio is greater than Aptorum Group Limited (-5.15), less than Applied Molecular Transport Inc. (-0.14), greater than Fresh Tracks Therapeutics, Inc. (-0.78), greater than BioCardia, Inc. (-0.61), greater than Virax Biolabs Group Limited (-1.09), less than Blue Water Vaccines, Inc. (-0.17), less than Revelation Biosciences, Inc. (-0.09), less than Hillstream BioPharma, Inc. (-0.00), less than Kiora Pharmaceuticals, Inc. (4.62), greater than Forte Biosciences, Inc. (-9.46), greater than Cellectar Biosciences, Inc. (-1.20), less than Diffusion Pharmaceuticals Inc. (-0.00), less than Tonix Pharmaceuticals Holding Corp. (-0.00), greater than Onconova Therapeutics, Inc. (-1.15), less than Jaguar Health, Inc. (-0.07), greater than Vaxart, Inc. (-2.32), less than VBI Vaccines Inc. (-0.02), greater than Pulmatrix, Inc. (-0.69), greater than Capricor Therapeutics, Inc. (-5.00), greater than Akari Therapeutics, Plc (-1.60), greater than Soleno Therapeutics, Inc. (-31.14),
| Company | PE Ratio | Market cap |
|---|---|---|
| -5.15 | $14.56M | |
| -0.14 | $11.01M | |
| -0.78 | $4.45M | |
| -0.61 | $9.81M | |
| -1.09 | $12.42M | |
| -0.17 | $3.41M | |
| -0.09 | $1.50M | |
| -0.00 | $4.17M | |
| 4.62 | $10.54M | |
| -9.46 | $10.70M | |
| -1.20 | $74.57M | |
| -0.00 | $8.98M | |
| -0.00 | $3.24M | |
| -1.15 | $20.90M | |
| -0.07 | $10.26M | |
| -2.32 | $216.07M | |
| -0.02 | $1.87M | |
| -0.69 | $7.45M | |
| -5.00 | $142.85M | |
| -1.60 | $41.66M | |
| -31.14 | $2.05B |
Build a custom stock screener for AIM ImmunoTech Inc. (AIM) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like AIM ImmunoTech Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
AIM ImmunoTech Inc. (AIM) and other stocks custom spreadsheet templates
The easiest way to analyze a company like AIM ImmunoTech Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the PE Ratio?
How can you use the PE Ratio?
What is AIM ImmunoTech Inc.'s PE Ratio?
How is the PE Ratio calculated for AIM ImmunoTech Inc. (AIM)?
What is the highest PE Ratio for AIM ImmunoTech Inc. (AIM)?
What is the 3-year average PE Ratio for AIM ImmunoTech Inc. (AIM)?
What is the 5-year average PE Ratio for AIM ImmunoTech Inc. (AIM)?
How does the current PE Ratio for AIM ImmunoTech Inc. (AIM) compare to its historical average?